MXPA05004126A - Uso de anticuerpos para la cadena 2 gamma de la laminina 5 para inhibir el crecimiento tumoral y la metastasis. - Google Patents

Uso de anticuerpos para la cadena 2 gamma de la laminina 5 para inhibir el crecimiento tumoral y la metastasis.

Info

Publication number
MXPA05004126A
MXPA05004126A MXPA05004126A MXPA05004126A MXPA05004126A MX PA05004126 A MXPA05004126 A MX PA05004126A MX PA05004126 A MXPA05004126 A MX PA05004126A MX PA05004126 A MXPA05004126 A MX PA05004126A MX PA05004126 A MXPA05004126 A MX PA05004126A
Authority
MX
Mexico
Prior art keywords
metastasis
tumor growth
chain
lallminin
antibodies
Prior art date
Application number
MXPA05004126A
Other languages
English (en)
Inventor
Tryggvason Karl
Original Assignee
Sirpa Salo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sirpa Salo filed Critical Sirpa Salo
Publication of MXPA05004126A publication Critical patent/MXPA05004126A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invencion proporciona un metodo y composiciones para inhibir el crecimiento tumoral y/o metastasis que involucra la administracion a un sujeto con una laminina 5 que secreta el tumor de una cantidad efectiva para inhibir el crecimiento tumoral y/o metastasis de un anticuerpo que une a uno o mas epitopes de la cadena (2 de la laminina 5.
MXPA05004126A 2002-10-29 2003-10-29 Uso de anticuerpos para la cadena 2 gamma de la laminina 5 para inhibir el crecimiento tumoral y la metastasis. MXPA05004126A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42200902P 2002-10-29 2002-10-29
PCT/EP2003/012012 WO2004039401A2 (en) 2002-10-29 2003-10-29 Use of antibodies to the gamma 2 chain of lallminin 5 to inhibit tumor growth and metastasis

Publications (1)

Publication Number Publication Date
MXPA05004126A true MXPA05004126A (es) 2005-10-18

Family

ID=32230306

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05004126A MXPA05004126A (es) 2002-10-29 2003-10-29 Uso de anticuerpos para la cadena 2 gamma de la laminina 5 para inhibir el crecimiento tumoral y la metastasis.

Country Status (6)

Country Link
EP (1) EP1578444A2 (es)
JP (1) JP2006511493A (es)
AU (1) AU2003286142A1 (es)
CA (1) CA2502088A1 (es)
MX (1) MXPA05004126A (es)
WO (1) WO2004039401A2 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007534631A (ja) * 2003-10-28 2007-11-29 ノボ　ノルディスク　アクティーゼルスカブ ラミニン−５γ２結合性ペプチド、その関連組成物およびその使用
WO2005052003A2 (en) * 2003-11-20 2005-06-09 Biostratum, Inc. Use of antibodies to the gamma 2 chain of laminin 5 to inhibit tumor growth and metastasis
JP2012530045A (ja) * 2008-06-18 2012-11-29 カール トゥリッグバソン， ラミニン−３３２のドメインに対する抗体
US20140045196A1 (en) * 2012-08-13 2014-02-13 University Of Tokyo Methods of prognosis and diagnosis of cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6955924B2 (en) * 1994-10-04 2005-10-18 Biostratum, Inc. Laminin chains: diagnostic uses
US5660982A (en) * 1994-10-04 1997-08-26 Tryggvason; Karl Laminin chains: diagnostic uses
WO2002030465A2 (en) * 2000-10-12 2002-04-18 University Of Rochester Compositions that inhibit proliferation of cancer cells
US7256001B2 (en) * 2001-08-17 2007-08-14 Eisai R&D Management Co., Ltd. Reagent for determining laminin 5 antigen in biological sample and assay method

Also Published As

Publication number Publication date
JP2006511493A (ja) 2006-04-06
WO2004039401A2 (en) 2004-05-13
EP1578444A2 (en) 2005-09-28
WO2004039401A3 (en) 2004-06-03
CA2502088A1 (en) 2004-05-13
AU2003286142A1 (en) 2004-05-25

Similar Documents

Publication Publication Date Title
IL244803B (en) Human anti-beta antibodies and their use
EP1575509A4 (en) EPHA2 AGONISTIC MONOCLONAL ANTIBODIES AND METHOD OF USE THEREOF
TW200509930A (en) Methods and compositions for treating rheumatoid arthritis
IL214325A (en) Antibody against cmet, a drug that includes and uses it
NZ595450A (en) Antibodies to M-CSF
TW200639182A (en) Antibody variants and uses thereof
UA94211C2 (ru) Выделенное полностью человеческое моноклональное cd3 антитело
ITMI20031127A1 (it) Anticorpi anti-hgf-r e loro uso
PL2161283T3 (pl) Kompozycja zawierająca przeciwciała przeciwko CD79b skoniugowane ze środkiem hamującym wzrost lub środkiem cytotoksycznym i sposoby leczenia guzów o pochodzeniu hematopoetycznym
EP1546205A4 (en) METHOD FOR THE CONTROL OF CANCER
MXPA05004126A (es) Uso de anticuerpos para la cadena 2 gamma de la laminina 5 para inhibir el crecimiento tumoral y la metastasis.
NZ593171A (en) Monoclonal antibody SC104 and derivative thereof specifically binding to a sialyltetraosyl carbohydrate as a potential anti-tumor therapeutic agent
WO2005052003A3 (en) Use of antibodies to the gamma 2 chain of laminin 5 to inhibit tumor growth and metastasis
UA98100C2 (ru) Гуманизированное моноклональное антитело, которое связывается с человеческим nogo и нейтрализует его
MA50374A (fr) Compositions d'anticorps pour le traitement de tumeurs
NZ593064A (en) Compositions and methods for the treatment of tumor of hematopoietic origin